Successfully reported this slideshow.
We use your LinkedIn profile and activity data to personalize ads and to show you more relevant ads. You can change your ad preferences anytime.
Update on Treatment for Lymphoma Lymphoma Support Ireland Meeting 19-02-2011 Dr. Greg Korpanty Medical Oncology Registrar ...
What is Lymphoma ? <ul><li>Lymphoma is a malignant transformation of  lymphocytes (white blood cells) </li></ul><ul><li>Ly...
 
 
 
 
CLP, common lymphoid precursor; BLB, pre-B lymphoblast; DN, CD4/CD8 double-negative pro-T cell; DP, CD4/CD8 double-positiv...
 
Classification of Lymphoma <ul><li>Histopathological </li></ul><ul><ul><li>NHL vs HL </li></ul></ul><ul><ul><li>B vs T-cel...
 
Histopathological classification Lymphoma Non-Hodgkin Lymphoma 85% Hodgkin Lymphoma 15% B-cell NHL 80% T-cell NHL 20%
 
New cases:  65,540 Deaths:  20,210
Etiology <ul><li>The exact etiology is unknown </li></ul><ul><li>Immune suppression </li></ul><ul><ul><li>congenital (Wisk...
Etiology <ul><li>Chronic inflammation </li></ul><ul><ul><li>Helicobacter pylori  (gastric NHL) </li></ul></ul><ul><ul><li>...
Diagnosis <ul><li>History </li></ul><ul><ul><li>fatigue </li></ul></ul><ul><ul><li>weight loss </li></ul></ul><ul><ul><li>...
Diagnosis <ul><li>Blood tests </li></ul><ul><li>- FBC, R/L  </li></ul><ul><li>-  LDH ,  uric acid </li></ul><ul><li>Bone m...
 
 
Treatment <ul><li>Multidisciplinary approach: </li></ul><ul><li>- pathology </li></ul><ul><li>- medical oncology </li></ul...
Follicular (indolent) lymphoma
Follicular lymphoma (FL) <ul><li>10-15% in Stage I or II </li></ul><ul><ul><li>potentially curable </li></ul></ul><ul><ul>...
Management of FL <ul><li>Observation – watch & wait </li></ul><ul><li>Local radiotherapy </li></ul><ul><li>Systemic chemot...
Rituximab
Rituximab
Bexxar, Zevalin
When we treat FL <ul><li>Symptoms </li></ul><ul><li>- fatigue </li></ul><ul><li>- pain </li></ul><ul><li>Organ dysfunction...
Bendamustine + Rituximab vs R-CHOP  in Indolent NHL  <ul><li>Regimen: bendamustine 90 mg/m 2  on Days 1 and 2 + Rituximab ...
Bendamustine + Rituximab vs R-CHOP in Indolent NHL: AEs  Rummel M, et al. ASH 2009. Abstract 405. Parameter Bendamustine +...
GELA PRIMA Phase III Study: Rituximab Maintenance in FL CHOP  x 6 + Rituximab  x 8 CVP  x 8 + Rituximab  x 8 FCM  x 6 + Ri...
Rituximab Maintenance for 2 Yrs:  PRIMA Phase III Study Salles GA, et al. ASCO 2010. Abstract 8004. At 2 yrs, rituximab ar...
 
Preliminary Analysis of Rituximab vs Watch and Wait in Asymptomatic FL Pts Ardeshna K, et al. ASH 2010. Abstract 6. Progre...
Bendamustine in Rituximab-Refractory NHL (Phase III Single-Arm Study) <ul><li>Pivotal evaluation of bendamustine for treat...
<ul><li>ORR  </li></ul><ul><ul><li>Patients with ≥ 1 dose of bendamustine (n = 100):  75% </li></ul></ul><ul><ul><li>Patie...
Rituximab ± Bortezomib in Relapsed, Rituximab-Naive or -Sensitive FL Coiffier B, et al. ASH 2010. Abstract 857. Rituximab ...
Results Coiffier B, et al. ASH 2010. Abstract 857. Response, n (%) Bort + Ritux (n = 315) Ritux  (n = 324) P Value ORR 199...
Grade ≥ 3 Toxicities <ul><li>Peripheral neuropathy </li></ul><ul><ul><li>Overall: 16% vs 1% in bortezomib + rituximab and ...
Post-Treatment FDG PET-CT as Predictor of PFS in FL: PRIMA Analysis <ul><li>PRIMA database reviewed  to identify PET-CT sc...
Diffuse Large B-Cell Lymphoma (DLBCL)
Management of DLBCL <ul><li>Systemic chemotherapy </li></ul><ul><li>Stem cell or bone marrow transplant </li></ul><ul><li>...
CHOP(R) Chemotherapy C yclophosphamide (Cytoxan) H ydroxydaunorubicin (Adriamycin) O ncovin (vincristine) P rednisone R it...
LNH 03-2B: R-ACVBP vs R-CHOP in Treatment-Naive Pts With CD20+ DLBCL <ul><li>Patients aged 18-59 yrs </li></ul><ul><li>No ...
LNH 03-2B Study: Results  Récher C, et al. ASH 2010. Abstract 109. 3-Yr PFS 1.0 Survival Probability 0.8 0.6 0.4 0.2 0 0 1...
T-Cell Lymphoma
 
 
Romidepsin in Progressive or Relapsed PTCL: Phase II Data <ul><li>Novel, bicyclic histone deacetylase inhibitor approved f...
Hodgkin’s Lymphoma
1798 - 1866 Thomas Hodgkin
HL <ul><li>One-seventh as common as NHL </li></ul><ul><li>Highly treatable and curable, even when disseminated </li></ul><...
Management of HL <ul><li>Radiotherapy </li></ul><ul><li>Systemic chemotherapy </li></ul><ul><li>Stem cell/bone marrow tran...
<ul><li>A driamycin (doxorubicin) </li></ul><ul><li>B leomycin </li></ul><ul><li>V inblastine </li></ul><ul><li>D acarbazi...
E2496: ABVD vs Stanford V ± Radiation Therapy in Advanced Hodgkin Lymphoma Gordon LI, et al. ASH 2010. Abstract 415. ABVD ...
E2496: Results <ul><li>ABVD remains standard of care  </li></ul><ul><li>5-yr FFS: higher for ABVD </li></ul><ul><li>Simila...
Brentuximab Vedotin (SGN-35) in Relapsed/ Refractory Hodgkin’s Lymphoma  <ul><li>Brentuximab vedotin anti-CD30 monoclonal ...
 
Brentuximab Vedotin (SGN-35) in Relapsed/Refractory HL: Results  <ul><li>94%  of patients achieved tumor reduction </li></...
Novel Therapies Under Investigation in Lymphomas
CAL-101 <ul><li>CAL-101: isoform-selective inhibitor of PI3K [1] </li></ul><ul><ul><li>Dosed at 50 mg BID up to 350 mg BID...
KW-0761 <ul><li>KW-0761: anti-CCXR4 monoclonal antibody </li></ul><ul><ul><li>Given at 1.0 mg/kg for 8 weekly infusions to...
Conclusions <ul><li>1. Selected group of DLBCL patients may benefit from more aggressive treatment than standard R-CHOP ch...
Thank You
Upcoming SlideShare
Loading in …5
×

Update on treatment for lymphoma, Lymphoma Support Ireland meeting - feb 2011 - pc

15,025 views

Published on

Presentation by Dr Greg Korpanty, Beaumont Hospital, Dublin on Update on Lymphoma Treatment to meeting Feb 19th 2011.

Published in: Health & Medicine
  • Be the first to comment

Update on treatment for lymphoma, Lymphoma Support Ireland meeting - feb 2011 - pc

  1. 1. Update on Treatment for Lymphoma Lymphoma Support Ireland Meeting 19-02-2011 Dr. Greg Korpanty Medical Oncology Registrar Beaumont Hospital
  2. 2. What is Lymphoma ? <ul><li>Lymphoma is a malignant transformation of lymphocytes (white blood cells) </li></ul><ul><li>Lymphocytes (B-cell and T-cell) </li></ul><ul><ul><li>involved in immune response to infection, transplanted organs or foreign bodies </li></ul></ul><ul><ul><li>They are carried through lymphatic system as well as the blood, so lymphoma can start both in lymph nodes and spread anywhere throughout the body </li></ul></ul><ul><ul><li>Lymphoma can also start in ANY solid organ of the body </li></ul></ul><ul><ul><li>- GI tract </li></ul></ul><ul><ul><li>- skin </li></ul></ul><ul><ul><li>- lung </li></ul></ul><ul><ul><li>- heart </li></ul></ul><ul><ul><li>- CNS </li></ul></ul><ul><ul><li>- bones </li></ul></ul>
  3. 7. CLP, common lymphoid precursor; BLB, pre-B lymphoblast; DN, CD4/CD8 double-negative pro-T cell; DP, CD4/CD8 double-positive pre-T cell; GC, germinal-center B cell; MC, mantle B cell; MZ, marginal zone B cell; NBC, naive B cell; PTC, peripheral T cell.
  4. 9. Classification of Lymphoma <ul><li>Histopathological </li></ul><ul><ul><li>NHL vs HL </li></ul></ul><ul><ul><li>B vs T-cell </li></ul></ul><ul><ul><li>CD20 +ve vs CD20 -ve </li></ul></ul><ul><ul><li>high grade vs low grade </li></ul></ul><ul><li>Clinical </li></ul><ul><ul><li>aggressive vs indolent </li></ul></ul><ul><ul><li>stage I vs IV </li></ul></ul><ul><li>Molecular </li></ul><ul><ul><li>c-myc gene translocation </li></ul></ul>
  5. 11. Histopathological classification Lymphoma Non-Hodgkin Lymphoma 85% Hodgkin Lymphoma 15% B-cell NHL 80% T-cell NHL 20%
  6. 13. New cases: 65,540 Deaths: 20,210
  7. 14. Etiology <ul><li>The exact etiology is unknown </li></ul><ul><li>Immune suppression </li></ul><ul><ul><li>congenital (Wiskott-Aldrich syndrome) </li></ul></ul><ul><ul><li>organ transplant (immunosupressants) </li></ul></ul><ul><ul><li>HIV infection </li></ul></ul><ul><ul><li>increasing age </li></ul></ul><ul><li>DNA repair defects </li></ul><ul><ul><li>ataxia telangiectasia </li></ul></ul><ul><ul><li>xeroderma pigmentosum </li></ul></ul>
  8. 15. Etiology <ul><li>Chronic inflammation </li></ul><ul><ul><li>Helicobacter pylori (gastric NHL) </li></ul></ul><ul><ul><li>Chlamydia psittaci (ocular, adnexal NHL) </li></ul></ul><ul><li>Viral causes </li></ul><ul><ul><li>EBV - Burkitt’s lymphoma </li></ul></ul><ul><ul><li>HTLV-I - T cell leukemia-lymphoma </li></ul></ul><ul><ul><li>HTLV-V - cutaneous T cell lymphoma </li></ul></ul><ul><ul><li>Hepatitis C </li></ul></ul>
  9. 16. Diagnosis <ul><li>History </li></ul><ul><ul><li>fatigue </li></ul></ul><ul><ul><li>weight loss </li></ul></ul><ul><ul><li>fevers </li></ul></ul><ul><ul><li>night sweats </li></ul></ul><ul><ul><li>lump </li></ul></ul><ul><li>Physical examination </li></ul><ul><ul><li>lump(s) </li></ul></ul><ul><ul><li>enlarged liver, spleen </li></ul></ul><ul><ul><li>pale skin; bruises </li></ul></ul>
  10. 17. Diagnosis <ul><li>Blood tests </li></ul><ul><li>- FBC, R/L </li></ul><ul><li>- LDH , uric acid </li></ul><ul><li>Bone marrow biopsy </li></ul><ul><li>Imaging </li></ul><ul><li>- CXR </li></ul><ul><li>- CT N/T/A/P </li></ul><ul><li>- PET/CT scan </li></ul>
  11. 20. Treatment <ul><li>Multidisciplinary approach: </li></ul><ul><li>- pathology </li></ul><ul><li>- medical oncology </li></ul><ul><li>- haematology </li></ul><ul><li>- radiation oncology </li></ul><ul><li>- radiology </li></ul><ul><li>Chemotherapy </li></ul><ul><li>- combination CT </li></ul><ul><li>- high dose CT + Bone marrow Tx </li></ul><ul><li>Radiotherapy </li></ul>
  12. 21. Follicular (indolent) lymphoma
  13. 22. Follicular lymphoma (FL) <ul><li>10-15% in Stage I or II </li></ul><ul><ul><li>potentially curable </li></ul></ul><ul><ul><li>local radiotherapy </li></ul></ul><ul><li>85-90% Stage III or IV </li></ul><ul><ul><li>incurable but treatable </li></ul></ul><ul><ul><li>treatment provides symptoms control </li></ul></ul>
  14. 23. Management of FL <ul><li>Observation – watch & wait </li></ul><ul><li>Local radiotherapy </li></ul><ul><li>Systemic chemotherapy </li></ul><ul><ul><li>IV agents: CHOP, CVP, fludarabine, cladribine. </li></ul></ul><ul><ul><li>oral agents: chlorambucil and prednisone </li></ul></ul><ul><li>Monoclonal antibody against CD20 </li></ul><ul><ul><li>Rituximab </li></ul></ul><ul><ul><li>Bexxar, Zevalin </li></ul></ul><ul><li>(Stem cell or bone marrow transplant) ? </li></ul>
  15. 24. Rituximab
  16. 25. Rituximab
  17. 26. Bexxar, Zevalin
  18. 27. When we treat FL <ul><li>Symptoms </li></ul><ul><li>- fatigue </li></ul><ul><li>- pain </li></ul><ul><li>Organ dysfunction </li></ul><ul><li>Cosmetic considerations </li></ul><ul><li>Low Hgb, Plts, WBC </li></ul>
  19. 28. Bendamustine + Rituximab vs R-CHOP in Indolent NHL <ul><li>Regimen: bendamustine 90 mg/m 2 on Days 1 and 2 + Rituximab on Day 1 every 28 days </li></ul>Rummel M, et al. ASH 2009. Abstract 405. Parameter Bendamustine + Rituximab R-CHOP P Value CR, % 39.6 30.0 .0262 Median PFS, mos 54.9 34.8 .00012
  20. 29. Bendamustine + Rituximab vs R-CHOP in Indolent NHL: AEs Rummel M, et al. ASH 2009. Abstract 405. Parameter Bendamustine + Rituximab R-CHOP P Value Grade 3/4 neutropenia, 10.7 46.5 < .0001 Grade 3/4 leukocytopenia, 12.1 38.2 < .0001 G-CSF use 4 20 < .0001 Infections, n 96 127 .0025 Erythema, n 42 23 .0122 Allergic skin reaction, n 40 15 .0003 Paresthesias, n 18 73 < .0001 Stomatitis 16 47 < .0001
  21. 30. GELA PRIMA Phase III Study: Rituximab Maintenance in FL CHOP x 6 + Rituximab x 8 CVP x 8 + Rituximab x 8 FCM x 6 + Rituximab x 8 Patients with previously untreated grade 1-3 FL (N = 1200) CR, PR RANDOMI ZED Maintenance Rituximab 375 mg/m 2 q2mo x 2 yrs Observation Available at: http://prima.gela.org.
  22. 31. Rituximab Maintenance for 2 Yrs: PRIMA Phase III Study Salles GA, et al. ASCO 2010. Abstract 8004. At 2 yrs, rituximab arm had significant improvements in time to next antilymphoma treatment and RR PFS 95% CI P Value Rituximab, % 82 (2 yrs) 78-86 < .0001 Observation, % 66 (2 yrs) 61-70 Grade 3/4 Adverse Events Rituximab Overall: 23% Neutropenia: 4% Infections: 4% Observation Overall: 16% Neutropenia: < 1% Infections: < 1%
  23. 33. Preliminary Analysis of Rituximab vs Watch and Wait in Asymptomatic FL Pts Ardeshna K, et al. ASH 2010. Abstract 6. Progression-free survival 1.0 0.9 0.8 0.7 0.6 0.5 0.4 0.3 0.2 0.1 0 0 1 2 3 4 5 Proportion of Patients Progression Free Yrs From Randomization 3-Yr PFS W + W: 33% R4: 60% R4 + RM: 81% W + W R4 R4 + RM Events 108 33 33 Pts 181 83 189
  24. 34. Bendamustine in Rituximab-Refractory NHL (Phase III Single-Arm Study) <ul><li>Pivotal evaluation of bendamustine for treatment of rituximab-refractory, indolent, B-cell NHL </li></ul><ul><li>Bendamustine 120 mg/m 2 given on Days 1 and 2 every 21 days </li></ul>Kahl BS, et al. Cancer. 2010;116:106-114.
  25. 35. <ul><li>ORR </li></ul><ul><ul><li>Patients with ≥ 1 dose of bendamustine (n = 100): 75% </li></ul></ul><ul><ul><li>Patients with ≥ PR to last regimen (n = 51): 88% </li></ul></ul><ul><ul><li>Patients with no response to last regimen (n = 36): 64% </li></ul></ul><ul><li>Response rates did not significantly differ by </li></ul><ul><li>histology </li></ul><ul><li>Median PFS: 9.3 mos </li></ul>Bendamustine in Rituximab-Refractory NHL: Phase III Results Kahl BS, et al. Cancer. 2010;116:106-114.
  26. 36. Rituximab ± Bortezomib in Relapsed, Rituximab-Naive or -Sensitive FL Coiffier B, et al. ASH 2010. Abstract 857. Rituximab 375 mg/m 2 Cycle 1: Days 1, 8, 15, 22 Cycles 2-5: Day 1 only Rituximab + Bortezomib Rituximab 375 mg/m 2 Cycle 1: Days 1, 8, 15, 22 Cycles 2-5: Day 1 only + Bortezomib 1.6 mg/m 2 Cycle 1: Days 1, 8, 15, 22 25 Wks Patients with relapsed, rituximab-naive or -sensitive FL (N = 670)
  27. 37. Results Coiffier B, et al. ASH 2010. Abstract 857. Response, n (%) Bort + Ritux (n = 315) Ritux (n = 324) P Value ORR 199 (63) 160 (49) < .001 CR 79 (25) 59 (18) .035 SD 78 (25) 120 (37) -- PD 38 (12) 44 (14) -- Overall durable response rate 159 (50) 124 (38) .002 Durable CR 76 (24) 54 (17) -- 100 90 80 70 60 50 40 30 20 10 0 48 0 3 6 9 12 15 18 21 24 27 30 33 36 39 42 45 Patients Without Event (%) Mos Median PFS (95% CI) 11.0 mos (9.1-12.0) 12.8 mos (11.5-15.0) Rituximab: Bortezomib-rituximab : HR: 0.822 (0.681-0.991; P = .039)
  28. 38. Grade ≥ 3 Toxicities <ul><li>Peripheral neuropathy </li></ul><ul><ul><li>Overall: 16% vs 1% in bortezomib + rituximab and rituximab pts, respectively </li></ul></ul><ul><ul><li>Most PN events were reversible in bortezomib pts </li></ul></ul>Coiffier B, et al. ASH 2010. Abstract 857. Adverse Event, n (%) Bortezomib + Rituximab (n = 334) Rituximab (n = 339) Constipation 1 (< 1) 0 Diarrhea 25 (7) 0 Fatigue 5 (1) 0 Nausea/Vomiting 10 (3) 2 (1) Neutropenia 37 (11) 15 (4) Febrile neutropenia 5 (1) 3 (1) Infections 36 (11) 15 (4) Herpes zoster 12 (4) 1 (< 1) Peripheral sensory neuropathy 9 (3) 0 Thrombocytopenia 10 (3) 2 (1)
  29. 39. Post-Treatment FDG PET-CT as Predictor of PFS in FL: PRIMA Analysis <ul><li>PRIMA database reviewed to identify PET-CT scans at staging and assessment for response post induction </li></ul><ul><li>277 scans (160 patients of total PRIMA population [N = 1217]) </li></ul><ul><li>Posttreatment PET shown to an independent predictor and stronger than other prognostic factors </li></ul>Trotman J, et al. ASH 2010. Abstract 855. Mos 60 0 6 12 18 24 30 36 42 48 54 1.0 0.8 0.6 0.4 0.2 0 Probability of PFS 74% 32% PET negative PET positive HR = 3.5 (95% CI: 2.0-6.1) P < .0001
  30. 40. Diffuse Large B-Cell Lymphoma (DLBCL)
  31. 41. Management of DLBCL <ul><li>Systemic chemotherapy </li></ul><ul><li>Stem cell or bone marrow transplant </li></ul><ul><li>Radiotherapy (palliative) </li></ul>
  32. 42. CHOP(R) Chemotherapy C yclophosphamide (Cytoxan) H ydroxydaunorubicin (Adriamycin) O ncovin (vincristine) P rednisone R ituximab
  33. 43. LNH 03-2B: R-ACVBP vs R-CHOP in Treatment-Naive Pts With CD20+ DLBCL <ul><li>Patients aged 18-59 yrs </li></ul><ul><li>No radiotherapy in either treatment arm </li></ul>Récher C, et al. ASH 2010. Abstract 109.
  34. 44. LNH 03-2B Study: Results Récher C, et al. ASH 2010. Abstract 109. 3-Yr PFS 1.0 Survival Probability 0.8 0.6 0.4 0.2 0 0 12 24 36 48 60 72 Mos P = .0015; HR: 0.482 R-ACVBP R-CHOP 3-Yr OS 1.0 Survival Probability 0.8 0.6 0.4 0.2 0 0 12 24 36 48 60 72 Mos P = .0071; HR: 0.439 R-ACVBP R-CHOP
  35. 45. T-Cell Lymphoma
  36. 48. Romidepsin in Progressive or Relapsed PTCL: Phase II Data <ul><li>Novel, bicyclic histone deacetylase inhibitor approved for cutaneous </li></ul><ul><li>T-cell lymphoma </li></ul><ul><li>Current trial: single-arm, international, open-label phase II study (N = 131) </li></ul><ul><li>Romidepsin given at 14 mg/m 2 (4-hr IV) on Days 1, 8, and 15 of a 28-day cycle for 6 cycles </li></ul>Coiffier B, et al. ASH 2010. Abstract 114. Response, n (%) IRC (N = 130) Investigators (N = 130) Objective response 34 (26) 38 (29) Complete response 17 (13) 21 (16) SD 32 (25) 22 (17) PD 64 (49) 70 (54)
  37. 49. Hodgkin’s Lymphoma
  38. 50. 1798 - 1866 Thomas Hodgkin
  39. 51. HL <ul><li>One-seventh as common as NHL </li></ul><ul><li>Highly treatable and curable, even when disseminated </li></ul><ul><li>Presence of Reed-Sternberg cell is mandatory for diagnosis. </li></ul>
  40. 52. Management of HL <ul><li>Radiotherapy </li></ul><ul><li>Systemic chemotherapy </li></ul><ul><li>Stem cell/bone marrow transplant </li></ul>
  41. 53. <ul><li>A driamycin (doxorubicin) </li></ul><ul><li>B leomycin </li></ul><ul><li>V inblastine </li></ul><ul><li>D acarbazine </li></ul>
  42. 54. E2496: ABVD vs Stanford V ± Radiation Therapy in Advanced Hodgkin Lymphoma Gordon LI, et al. ASH 2010. Abstract 415. ABVD 6-8 cycles modified IFRT 36 Gy only in patients with massive mediastinal disease (n = 404) Stanford V - MOPPEBVCAD 12 wks’ chemotherapy, modified IFRT 36 Gy to sites > 5 cm in max transverse dimension (n = 408) *Defined as mass ≥ 1/3 maximum intrathoracic diameter on standing PA chest x-ray. Previously untreated patients with histologically proven HL, advanced or locally extensive disease, massive mediastinal adenopathy* (N = 812)
  43. 55. E2496: Results <ul><li>ABVD remains standard of care </li></ul><ul><li>5-yr FFS: higher for ABVD </li></ul><ul><li>Similar rates of toxicity between treatment arms </li></ul><ul><ul><li>Higher rates of grade 3 lymphopenia sensory neuropathy with Stanford V </li></ul></ul>Gordon LI, et al. ASH 2010. Abstract 415. Measure, % ABVD Stanford V Response* CR + CCR 72.0 69.0 PR 7.7 7.4 SD 7.9 10.3 PD < 1.0 2.0 5-yr FFS* 73.0 71.0 5-yr OS* 88.0 87.0
  44. 56. Brentuximab Vedotin (SGN-35) in Relapsed/ Refractory Hodgkin’s Lymphoma <ul><li>Brentuximab vedotin anti-CD30 monoclonal antibody </li></ul><ul><li>Primary endpoint: overall objective response rate (CR + PR) by independent review facility </li></ul><ul><li>Secondary endpoints: OS and PFS </li></ul>Chen R, et al. ASH 2010. Abstract 283. Brentuximab vedotin 1.8 mg/kg Administered every 21 days on outpatient basis over 30 min for a max of 16 cycles until at least SD achieved; patients restaged at cycles 2, 4, 7, 10, 13, 16 Follow-up every 12 wks Patients with relapsed/ refractory CD30+ disease, 12 yrs of age or older, measurable disease ≥ 1.5 cm, ECOG PS 0-1, previous ASCT (N = 102)
  45. 58. Brentuximab Vedotin (SGN-35) in Relapsed/Refractory HL: Results <ul><li>94% of patients achieved tumor reduction </li></ul><ul><li>Median treatment cycles: 9 (range: 1-16) </li></ul>Chen R, et al. ASH 2010. Abstract 283. Wks 70 0 10 20 30 40 50 60 Patients Free of PD or Death (%) 100 90 80 70 60 50 40 30 20 10 0 OS PFS per investigator PFS per IRF Median, Wks Not reached 39.1 25.1 Response, % Inv. IRF ORR 72 75 CR 33 34 PR 38 40 SD 27 22 PD 0 3 Not evaluable 1 1
  46. 59. Novel Therapies Under Investigation in Lymphomas
  47. 60. CAL-101 <ul><li>CAL-101: isoform-selective inhibitor of PI3K [1] </li></ul><ul><ul><li>Dosed at 50 mg BID up to 350 mg BID at 50-mg increments in a phase I trial in 55 patients with relapsed/refractory NHL </li></ul></ul><ul><ul><li>Partial responses seen at all doses </li></ul></ul><ul><ul><li>Grade ≥ 3 adverse events included neutropenia, lymphopenia, and thrombocytopenia </li></ul></ul>1. Kahl BS, et al. ASH 2010. Abstract 1777.
  48. 61. KW-0761 <ul><li>KW-0761: anti-CCXR4 monoclonal antibody </li></ul><ul><ul><li>Given at 1.0 mg/kg for 8 weekly infusions to 27 patients with relapsed T-cell lymphoma in a phase II trial </li></ul></ul><ul><ul><li>ORR: 14 patients (7 CR, 7 PR) </li></ul></ul>Ishida T, et al. ASH 2010. Abstract 285.
  49. 62. Conclusions <ul><li>1. Selected group of DLBCL patients may benefit from more aggressive treatment than standard R-CHOP chemotherapy </li></ul><ul><li>2. New agents are being evaluated for relapsed disease (conjugated monoclonal Abs and small molecule oral drugs) with promising results in early phase clinical trials </li></ul>
  50. 63. Thank You

×